Keyword Analysis & Research: 4dmt
Keyword Research: People who searched 4dmt also searched
Search Results related to 4dmt on Search Engine
-
4DMT | Powering The Future Of Genetic Medicines
https://4dmoleculartherapeutics.com/
WebNew era of genetic medicine. Driven by our innovative vector platform and efficient product design and development engine, we are inventing and developing genetic medicines with proprietary customized vectors that are optimized for the specific diseases we treat.
DA: 64 PA: 47 MOZ Rank: 9
-
Pipeline | 4DMT - 4D Molecular Therapeutics
https://4dmoleculartherapeutics.com/pipeline/
WebOur diversified product pipeline spans three therapeutic areas, each of which leverages a unique and proprietary customized vector invented at 4DMT. Each product candidate is administered by one of three different routes of administration based on the disease target: intravitreal (for ophthalmology), aerosol delivery (for pulmonology) and ...
DA: 37 PA: 11 MOZ Rank: 32
-
About | 4DMT - 4D Molecular Therapeutics
https://4dmoleculartherapeutics.com/about/
WebJan 3, 2024 · 4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases.
DA: 56 PA: 61 MOZ Rank: 25
-
4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance
https://finance.yahoo.com/quote/FDMT/
Web4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The...
DA: 21 PA: 35 MOZ Rank: 30
-
Press Releases | 4D Molecular Therapeutics
https://ir.4dmoleculartherapeutics.com/press-releases
WebEMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will. More.
DA: 67 PA: 93 MOZ Rank: 21
-
Investors & Media | 4D Molecular Therapeutics
https://ir.4dmt.com/
WebMarch 28, 2024. 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis. March 4, 2024. 4DMT to Participate in Upcoming Investor Conferences. February 29, 2024. 4DMT Reports Full Year 2023 Financial Results and Operational Highlights. Events. More events are coming soon. …
DA: 3 PA: 19 MOZ Rank: 49
-
4DMT Presents Positive Interim Data from Randomized Phase 2 …
https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-presents-positive-interim-data-randomized-phase-2-prism
WebEMERYVILLE, Calif., Feb. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive interim data from the Phase 2 PRISM clinical trial ...
DA: 69 PA: 55 MOZ Rank: 22
-
Release Details - 4D Molecular Therapeutics
https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-updates-clinical-pipeline
WebEMERYVILLE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced product pipeline portfolio updates and preclinical product candidate additions for its large market ophthalmology …
DA: 68 PA: 35 MOZ Rank: 49
-
4D Molecular Therapeutics | LinkedIn
https://www.linkedin.com/company/4d-molecular-therapeutics-llc
WebAbout us. 4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases.
DA: 57 PA: 80 MOZ Rank: 29
-
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold
https://www.globenewswire.com/news-release/2023/10/30/2769166/0/en/4DMT-Gains-Alignment-with-FDA-on-Plan-to-Lift-Clinical-Hold-on-Phase-1-2-INGLAXA-Clinical-Trial-for-4D-310-for-Fabry-Disease-Cardiomyopathy.html
WebEMERYVILLE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted...
DA: 74 PA: 23 MOZ Rank: 6